Robin M Nance1, Vani Vannappagari2, Kimberly Smith2, Catherine B Johannes3, Brian Calingaert4, Catherine W Saltus4, Kenneth H Mayer5, Bridget M Whitney1, Benigno Rodriguez6, Richard D Moore7, Joseph J Eron8, Elvin Geng9, William Christopher Mathews10, Michael J Mugavero11, Michael S Saag11, Mari M Kitahata12, Joseph A C Delaney1, Heidi M Crane12. 1. University of Washington, Collaborative Health Studies Coordinating Center, Seattle, WA. 2. ViiV Healthcare, Research Triangle Park, NC. 3. RTI Health Solutions, Waltham, MA. 4. RTI Health Solutions, Research Triangle Park, NC. 5. Department of Medicine, Harvard Medical School, Fenway Institute, Boston, MA. 6. Department of Medicine, Case Western University, Cleveland, OH. 7. Department of Medicine, Johns Hopkins, Baltimore, MD. 8. Department of Medicine, University of North Carolina, Chapel Hill, NC. 9. Department of Medicine, University of California San Francisco, San Francisco, CA. 10. Department of Medicine, University of California San Diego, UCSD Medical Center, San Diego, CA. 11. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL. 12. Department of Medicine, University of Washington, Seattle, WA.
Abstract
BACKGROUND: Guidelines for initial antiretroviral treatment (ART) regimens have evolved, with integrase strand transfer inhibitors (INSTIs) increasingly prominent. Research on virologic failure (VF) with INSTI therapy is predominantly from clinical trials not care settings, especially for recently approved medications including dolutegravir. We compared outcomes among people living with HIV (PLWH) who initiated recommended regimens in clinical care across the United States. SETTING: We examined 2 groups of PLWH at 8 clinics who initiated ART regimens (August 1, 2013-March 31, 2017): those ART treatment-naive at initiation, and those treatment-experienced. METHODS: The outcome in this longitudinal cohort study was VF, defined as a viral load of ≥400 copies/mL ≥6 months after ART initiation. We examined the proportion of individuals who remained on, switched, or discontinued the regimen. Associations between regimens and outcomes were examined with adjusted Cox proportional hazards models. RESULTS: Among 5177 PLWH, a lower proportion experienced VF on dolutegravir- versus other INSTI- or darunavir-based regimens for previously treatment-naive (7% vs. 12% vs. 28%) and treatment-experienced PLWH (6% vs. 10% vs. 21%). In adjusted analyses, hazard ratios were similar across regimens for the combined outcome of regimen discontinuation or treatment switch. The hazard ratios for VF comparing dolutegravir- to darunavir-based regimens was 0.30 (95% CI: 0.2 to 0.6) among previously treatment-naive PLWH and was 0.60 (95% CI: 0.4 to 0.8) among treatment-experienced PLWH. CONCLUSIONS: The proportion of previously treatment-naive PLWH remaining on recommended ART regimens did not differ by regimen. The likelihood of VF was lower with dolutegravir- than darunavir-based regimens for previously treatment-naive and treatment-experienced PLWH.
BACKGROUND: Guidelines for initial antiretroviral treatment (ART) regimens have evolved, with integrase strand transfer inhibitors (INSTIs) increasingly prominent. Research on virologic failure (VF) with INSTI therapy is predominantly from clinical trials not care settings, especially for recently approved medications including dolutegravir. We compared outcomes among people living with HIV (PLWH) who initiated recommended regimens in clinical care across the United States. SETTING: We examined 2 groups of PLWH at 8 clinics who initiated ART regimens (August 1, 2013-March 31, 2017): those ART treatment-naive at initiation, and those treatment-experienced. METHODS: The outcome in this longitudinal cohort study was VF, defined as a viral load of ≥400 copies/mL ≥6 months after ART initiation. We examined the proportion of individuals who remained on, switched, or discontinued the regimen. Associations between regimens and outcomes were examined with adjusted Cox proportional hazards models. RESULTS: Among 5177 PLWH, a lower proportion experienced VF on dolutegravir- versus other INSTI- or darunavir-based regimens for previously treatment-naive (7% vs. 12% vs. 28%) and treatment-experienced PLWH (6% vs. 10% vs. 21%). In adjusted analyses, hazard ratios were similar across regimens for the combined outcome of regimen discontinuation or treatment switch. The hazard ratios for VF comparing dolutegravir- to darunavir-based regimens was 0.30 (95% CI: 0.2 to 0.6) among previously treatment-naive PLWH and was 0.60 (95% CI: 0.4 to 0.8) among treatment-experienced PLWH. CONCLUSIONS: The proportion of previously treatment-naive PLWH remaining on recommended ART regimens did not differ by regimen. The likelihood of VF was lower with dolutegravir- than darunavir-based regimens for previously treatment-naive and treatment-experienced PLWH.
Authors: Jan van Lunzen; Franco Maggiolo; José R Arribas; Aza Rakhmanova; Patrick Yeni; Benjamin Young; Jürgen K Rockstroh; Steve Almond; Ivy Song; Cindy Brothers; Sherene Min Journal: Lancet Infect Dis Date: 2011-10-20 Impact factor: 25.071
Authors: Jürgen K Rockstroh; Edwin DeJesus; Jeffrey L Lennox; Yazdan Yazdanpanah; Michael S Saag; Hong Wan; Anthony J Rodgers; Monica L Walker; Michael Miller; Mark J DiNubile; Bach-Yen Nguyen; Hedy Teppler; Randi Leavitt; Peter Sklar Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: Andrew R Zolopa; Daniel S Berger; Harry Lampiris; Lijie Zhong; Steven L Chuck; Jeffrey V Enejosa; Brian P Kearney; Andrew K Cheng Journal: J Infect Dis Date: 2010-03-15 Impact factor: 5.226
Authors: Kendra E Hightower; Ruolan Wang; Felix Deanda; Brian A Johns; Kurt Weaver; Yingnian Shen; Ginger H Tomberlin; H Luke Carter; Timothy Broderick; Scott Sigethy; Takahiro Seki; Masanori Kobayashi; Mark R Underwood Journal: Antimicrob Agents Chemother Date: 2011-08-01 Impact factor: 5.191
Authors: Edwin DeJesus; Jürgen K Rockstroh; Jeffrey L Lennox; Michael S Saag; Adriano Lazzarin; Jing Zhao; Hong Wan; Anthony J Rodgers; Monica L Walker; Michael Miller; Mark J DiNubile; Bach-Yen Nguyen; Hedy Teppler; Randi Leavitt; Peter Sklar Journal: HIV Clin Trials Date: 2012 Jul-Aug
Authors: Andrew Zolopa; Paul E Sax; Edwin DeJesus; Anthony Mills; Calvin Cohen; David Wohl; Joel E Gallant; Hui C Liu; Andrew Plummer; Kirsten L White; Andrew K Cheng; Martin S Rhee; Javier Szwarcberg Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: Francois Raffi; Anita Rachlis; Hans-Jürgen Stellbrink; W David Hardy; Carlo Torti; Chloe Orkin; Mark Bloch; Daniel Podzamczer; Vadim Pokrovsky; Federico Pulido; Steve Almond; David Margolis; Clare Brennan; Sherene Min Journal: Lancet Date: 2013-01-08 Impact factor: 79.321
Authors: Mari M Kitahata; Benigno Rodriguez; Richard Haubrich; Stephen Boswell; W Christopher Mathews; Michael M Lederman; William B Lober; Stephen E Van Rompaey; Heidi M Crane; Richard D Moore; Michael Bertram; James O Kahn; Michael S Saag Journal: Int J Epidemiol Date: 2008-02-08 Impact factor: 7.196
Authors: Anthony M Mills; Kathy L Schulman; Jennifer S Fusco; Michael B Wohlfeiler; Julie L Priest; Alan Oglesby; Laurence Brunet; Philip C Lackey; Gregory P Fusco Journal: Open Forum Infect Dis Date: 2021-07-09 Impact factor: 3.835
Authors: Kristina L Bajema; Robin M Nance; Joseph A C Delaney; Ellen Eaton; Thibaut Davy-Mendez; Maile Y Karris; Richard D Moore; Joseph J Eron; Benigno Rodriguez; Kenneth H Mayer; Elvin Geng; Cindy Garris; Michael S Saag; Heidi M Crane; Mari M Kitahata Journal: AIDS Date: 2020-11-15 Impact factor: 4.632